Decheng Capital Management Iii (cayman) 13F annual report
Decheng Capital Management Iii (cayman) is an investment fund managing more than $300 billion ran by Jessie Qiu. There are currently 26 companies in Mrs. Qiu’s portfolio. The largest investments include Alpine Immune Sciences Inc and Zentalis Pharmaceuticals, Llc, together worth $119 billion.
$300 billion Assets Under Management (AUM)
As of 5th December 2023, Decheng Capital Management Iii (cayman)’s top holding is 6,708,288 shares of Alpine Immune Sciences Inc currently worth over $76.8 billion and making up 25.6% of the portfolio value.
Relative to the number of outstanding shares of Alpine Immune Sciences Inc, Decheng Capital Management Iii (cayman) owns more than 0.1% of the company.
In addition, the fund holds 2,099,583 shares of Zentalis Pharmaceuticals, Llc worth $42.1 billion, whose value fell 46.3% in the past six months.
The third-largest holding is Aura Biosciences, Inc. worth $18.2 billion and the next is Roivant Sciences Ltd worth $17 billion, with 1,459,700 shares owned.
Currently, Decheng Capital Management Iii (cayman)'s portfolio is worth at least $300 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Decheng Capital Management Iii (cayman)
The Decheng Capital Management Iii (cayman) office and employees reside in Grand Cayman, Cayman Islands. According to the last 13-F report filed with the SEC, Jessie Qiu serves as the Chief Compliance Officer at Decheng Capital Management Iii (cayman).
Recent trades
In the most recent 13F filing, Decheng Capital Management Iii (cayman) revealed that it had opened a new position in
Alpine Immune Sciences Inc and bought 6,708,288 shares worth $76.8 billion.
This means they effectively own 0.1% of the company.
Alpine Immune Sciences Inc makes up
37.9%
of the fund's Health Care sector allocation and has grown its share price by 180.5% in the past year.
The investment fund also strengthened its position in Aura Biosciences, Inc. by buying
869,790 additional shares.
This makes their stake in Aura Biosciences, Inc. total 1,163,123 shares worth $18.2 billion.
On the other hand, there are companies that Decheng Capital Management Iii (cayman) is getting rid of from its portfolio.
Decheng Capital Management Iii (cayman) closed its position in Alpine Immune Sciences Inc on 12th December 2023.
It sold the previously owned 6,708,288 shares for $69 billion.
Jessie Qiu also disclosed a decreased stake in Acelyrin Inc(nsm) by approximately 0.1%.
This leaves the value of the investment at $15.7 billion and 1,548,317 shares.
One of the smaller hedge funds
The two most similar investment funds to Decheng Capital Management Iii (cayman) are Hel Ved Capital Management Ltd and Univest Financial Corp. They manage $300 billion and $300 billion respectively.
Jessie Qiu investment strategy
Decheng Capital Management Iii (cayman)’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 67.7% of
the total portfolio value.
The fund focuses on investments in the United States as
50.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
12% of the total holdings value.
On the other hand, large-cap stocks make up only 7.7% of the portfolio.
The average market cap of the portfolio companies is close to $4.47 billion.
The complete list of Decheng Capital Management Iii (cayman) trades based on 13F SEC filings
These positions were updated on December 12th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Alpine Immune Sciences Inc |
Opened
6,708,288
|
$76,809,898,000 | 25.63% |
| Alpine Immune Sciences Inc |
Closed
6,708,288
|
$68,961,201,000 | |
| Zentalis Pharmaceuticals, Llc |
No change
2,099,583
|
$42,117,635,000 | 14.06% |
| Aura Biosciences, Inc. |
296.52%
1,163,123
|
$18,243,928,000 | 6.09% |
| Arcus Biosciences Inc |
Closed
869,790
|
$17,665,435,000 | |
| Roivant Sciences Ltd |
Opened
1,459,700
|
$17,049,296,000 | 5.69% |
| Acelyrin Inc(nsm) |
0.39%
1,548,317
|
$15,746,384,000 | 5.26% |
| Arcus Biosciences Inc |
Opened
869,790
|
$15,612,731,000 | 5.21% |
| 10x Genomics, Inc. |
No change
359,554
|
$14,831,603,000 | 4.95% |
| Roivant Sciences Ltd |
Closed
1,459,700
|
$14,713,776,000 | |
| Argenx Se |
No change
27,429
|
$13,484,919,000 | 4.50% |
| Pacific Biosciences of California Inc |
No change
1,463,872
|
$12,223,331,000 | 4.08% |
| Illumnia, Inc. |
No change
80,859
|
$11,100,324,000 | 3.70% |
| Lantheus Holdings Inc(nms) |
Opened
142,196
|
$9,879,778,000 | 3.30% |
| Horizon Therapeutics Plc |
No change
78,900
|
$9,127,941,000 | 3.05% |
| Phathom Pharmaceuticals Inc |
No change
850,000
|
$8,814,500,000 | 2.94% |
| Immunogen, Inc. |
Opened
415,880
|
$6,600,016,000 | 2.20% |
| BeyondSpring Inc |
Closed
4,958,143
|
$5,850,609,000 | |
| Seagen Inc |
Opened
23,014
|
$4,882,420,000 | 1.63% |
| Seagen Inc |
Closed
23,014
|
$4,429,274,000 | |
| Cue Health Inc. |
No change
8,980,909
|
$3,969,798,000 | 1.32% |
| BeyondSpring Inc |
Opened
4,958,143
|
$3,966,514,000 | 1.32% |
| Terns Pharmaceuticals, Inc. |
No change
714,285
|
$3,592,854,000 | 1.20% |
| Equillium Inc |
No change
4,447,308
|
$3,291,008,000 | 1.10% |
| Aadi Bioscience, Inc. |
No change
526,329
|
$2,547,432,000 | 0.85% |
| Atricure Inc |
Closed
46,259
|
$2,283,344,000 | |
| Atricure Inc |
Opened
46,259
|
$2,026,144,000 | 0.68% |
| Scynexis Inc |
No change
555,555
|
$1,266,665,000 | 0.42% |
| Mersana Therapeutics Inc |
No change
904,268
|
$1,148,420,000 | 0.38% |
| Apexigen, Inc. |
Closed
1,894,551
|
$814,278,000 | |
| Pyxis Oncology, Inc (formerly Apexigen) |
Opened
326,810
|
$650,352,000 | 0.22% |
| Genedx Holdings Corp. |
Closed
103,604
|
$617,479,000 | |
| Genedx Holdings Corp. |
Opened
103,604
|
$377,118,000 | 0.13% |
| Adicet Bio, Inc. |
60.41%
200,201
|
$274,275,000 | 0.09% |
| NeuBase Therapeutics, Inc. |
Closed
50,000
|
$92,500,000 | |
| No transactions found | |||
| Showing first 500 out of 35 holdings | |||
Hedge funds similar to Decheng Capital Management Iii (cayman)
- Sc&h Advisors
- Rosenberg Matthew Hamilton
- Optas
- Juniper Hill Capital Management L.P.
- Monetary Management Group Inc
- Steamboat Capital Partners
- Oak Hill Wealth Advisors
- Hel Ved Capital Management Ltd
- Univest Financial Corp
- Broadleaf Partners
- Af Advisors
- Cook Street Consulting
- Shulman Demeo Asset Management
- Immersion Capital LL.P.